A detailed history of Wolverine Trading, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 10,701 shares of NTLA stock, worth $128,947. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,701
Previous 11,469 6.7%
Holding current value
$128,947
Previous $256,000 14.45%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.72 - $27.36 $15,144 - $21,012
-768 Reduced 6.7%
10,701 $219,000
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $11,431 - $15,542
571 Added 5.24%
11,469 $256,000
Q1 2024

May 15, 2024

SELL
$23.82 - $32.8 $21,747 - $29,946
-913 Reduced 7.73%
10,898 $299,000
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $23,808 - $33,245
1,028 Added 9.53%
11,811 $360,000
Q3 2023

Nov 15, 2023

BUY
$31.62 - $45.78 $136,440 - $197,540
4,315 Added 66.71%
10,783 $340,000
Q2 2023

Aug 23, 2023

BUY
$34.58 - $46.03 $223,663 - $297,722
6,468 New
6,468 $263,000
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $123,507 - $233,144
3,719 Added 87.61%
7,964 $278,000
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $12,455 - $16,562
-231 Reduced 5.16%
4,245 $235,000
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $27,674 - $54,794
-719 Reduced 13.84%
4,476 $235,000
Q1 2022

May 16, 2022

SELL
$58.27 - $118.99 $21,093 - $43,074
-362 Reduced 6.51%
5,195 $375,000
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $99,953 - $137,253
-992 Reduced 15.15%
5,557 $674,000
Q3 2021

Nov 12, 2021

BUY
$132.37 - $176.78 $566,146 - $756,088
4,277 Added 188.25%
6,549 $901,000
Q2 2021

Aug 06, 2021

SELL
$60.88 - $161.91 $371,368 - $987,651
-6,100 Reduced 72.86%
2,272 $344,000
Q1 2021

May 14, 2021

BUY
$46.59 - $83.68 $390,051 - $700,568
8,372 New
8,372 $605,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $916M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.